Semax Research Guide: ACTH Analog, BDNF Mechanism & Nootropic Studies

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a stable, CNS-active analog of the ACTH(4-10) fragment of adrenocorticotropic hormone. Like Selank, which shares the Pro-Gly-Pro stabilizing tail, Semax has been registered as a pharmaceutical in Russia for neurological indications including ischemic stroke, cognitive impairment, and optic nerve disease. Its robust BDNF-inducing and neuroprotective profile, combined with substantial animal and clinical research, make it a frequently studied nootropic and neuroprotective research tool.

For research use only. Not intended for human or veterinary use.

Background: ACTH Fragments and Neuropeptide Design

Adrenocorticotropic hormone (ACTH) is a 39-amino acid pituitary peptide best known for stimulating cortisol secretion from the adrenal cortex. However, research from the 1960s onward, particularly by de Wied and colleagues, established that ACTH fragments lacking adrenocortical activity exerted significant effects on learning, memory, attention, and stress adaptation in animal models. The ACTH(4-10) sequence (Met-Glu-His-Phe-Pro-Gly) was identified as the core neuroactive fragment; Semax is its heptapeptide extension with a Pro-Gly-Pro tail, designed to extend plasma half-life from minutes to hours while preserving and amplifying CNS activity.

Structure and Pharmacokinetics

• Sequence: Met-Glu-His-Phe-Pro-Gly-Pro (7 amino acids; ACTH 4-7 core + Pro-Gly-Pro tail)
• Molecular weight: 887.0 Da
• Administration routes studied: Intranasal (primary, direct CNS delivery via olfactory pathway); subcutaneous; intravenous
• Half-life: Minutes in peripheral plasma; intranasal route delivers peptide directly to CNS via olfactory-brain transport, extending effective CNS exposure
• ACTH/cortisol effects: Absent, Semax does not stimulate adrenocortical hormone release
• Regulatory status: Registered pharmaceutical in Russia (stroke, cognitive impairment, optic nerve disease indications)

Mechanism of Action

BDNF and NGF Upregulation

The most extensively characterized mechanism of Semax is its potent induction of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression in multiple CNS regions. Dolotov et al. (2006) demonstrated that intranasal Semax administration produced rapid, sustained increases in BDNF mRNA and protein levels in the rat hippocampus, frontal cortex, and striatum, regions critical for memory, executive function, and motor control. The magnitude of BDNF induction reported in these studies was substantial, comparable to effects of physical exercise, antidepressants, and direct neurotrophic factor infusion, positioning Semax as one of the more potent pharmacological BDNF inducers identified in the peptide literature.

BDNF upregulation in the hippocampus promotes long-term potentiation (LTP), the synaptic strengthening mechanism underlying memory formation, and supports neuronal survival via TrkB receptor signaling. NGF upregulation similarly promotes cholinergic neuron survival and axonal integrity, with relevance to research on cognitive aging and neurodegenerative disease models.

Dopaminergic and Serotonergic Modulation

Semax modulates monoamine neurotransmitter systems in regions governing attention, motivation, and executive function. Research has documented increased dopamine turnover in the striatum and prefrontal cortex following Semax administration, consistent with enhanced dopaminergic tone in circuits involved in working memory and attention. Serotonergic effects have also been reported, with Semax influencing serotonin metabolism and receptor sensitivity in limbic regions, providing a mechanistic basis for its reported effects on stress resilience and mood-related endpoints in animal models.

Anti-inflammatory and Neuroprotective Mechanisms

Semax has demonstrated anti-neuroinflammatory properties in CNS injury models, including downregulation of pro-inflammatory cytokine expression (IL-1β, TNF-α) and upregulation of anti-inflammatory mediators in ischemic tissue. These effects, combined with BDNF/NGF-mediated neuronal survival signaling, contribute to the neuroprotective profile that supports its clinical use in acute stroke and ischemia research. Transcriptomic studies in rodent stroke models have documented broad gene expression changes following Semax treatment, including upregulation of genes involved in synaptic plasticity, anti-apoptosis, and energy metabolism.

Key Research Findings

Cognitive Enhancement and Memory

Numerous animal studies have examined Semax’s effects on learning and memory across multiple paradigms (Morris water maze, radial arm maze, conditioned avoidance, passive avoidance). Consistently, Semax-treated animals demonstrate superior acquisition and retention of spatial and associative memory tasks, with effects attributed to hippocampal BDNF upregulation and enhanced LTP. Performance improvements have been documented both in normal animals and in models of cognitive impairment induced by cholinergic depletion, aging, or hypoxia, a cross-model consistency that strengthens the mechanistic argument for memory enhancement.

Ischemic Stroke (Clinical)

Semax’s most clinically validated application is in acute ischemic stroke. Russian clinical trials have examined intranasal Semax administration in the acute and subacute stroke phases, documenting improved neurological recovery scores, reduced infarct-associated deficits, and faster functional rehabilitation in treated versus control patients. The proposed mechanisms involve both acute neuroprotection (anti-inflammatory, anti-apoptotic) and subacute neuroplasticity enhancement (BDNF-mediated circuit reorganization). Semax is currently used in Russian neurological clinical practice for stroke and is included in treatment guidelines for ischemic cerebrovascular disease.

Attention and ADHD Models

Semax’s dopaminergic and BDNF-mediated effects in prefrontal cortex circuits have generated research interest in attention and executive function. Animal studies using spontaneously hypertensive rats (SHR, a standard ADHD model) have demonstrated normalization of attention and impulsivity deficits following Semax administration. Early clinical observations in children with ADHD reported improvements in attention, behavioral regulation, and academic performance in Semax-treated subjects, though these reports require validation in larger controlled trials before firm conclusions can be drawn.

Optic Nerve and Visual Research

Consistent with its NGF-upregulating and neuroprotective properties, Semax has been studied and registered for optic nerve disease in Russia. Animal models of optic nerve ischemia and glaucoma have demonstrated reduced retinal ganglion cell death and preserved visual function in Semax-treated groups. NGF is critical for retinal ganglion cell survival, and Semax’s NGF-inducing activity provides mechanistic grounding for this ophthalmic research application.

Semax vs. Selank: Complementary Profiles

Reconstitution Protocol

Semax for research purposes is supplied as a lyophilized powder requiring reconstitution with bacteriostatic water.

• Inject bacteriostatic water slowly along the inner wall of the vial, do not direct the stream onto the lyophilized powder
• Gently swirl until fully dissolved; solution should be clear and colorless
• Common research concentration: 0.1% solution (1 mg/mL) for intranasal delivery models; higher for parenteral protocols
• Refrigerate reconstituted solution at 2–8°C; stable approximately 4 weeks; protect from light
• Do not freeze reconstituted solution

References

• Dolotov, O. V., Karpenko, E. A., Inozemtseva, L. S., Seredenina, T. S., Levitskaya, N. G., Rozyczka, J., … & Grivennikov, I. A. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Behavioral Brain Research, 166(1), 63–71.
• Sebentsova, E. A., Dolotov, O. V., Inozemtseva, L. S., Levitskaya, N. G., Andreeva, L. A., Kamenskii, A. A., & Grivennikov, I. A. (2008). Intranasal administration of semax, an analog of ACTH(4-7), improves the condition of rats with incomplete global ischemia. Journal of Physiological Sciences, 58(6), 378–385.
• Gusev, E. I., Skvortsova, V. I., Miasoedov, N. F., Nezavibatko, V. N., Zhuravleva, E. J., & Vanichkin, A. V. (1997). Effectiveness of semax in acute period of hemispheric ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 97(6), 26–34.
• Levitskaya, N. G., Sebentsova, E. A., Andreeva, L. A., Alfeeva, L. Y., Kamenskii, A. A., & Myasoedov, N. F. (2004). Analysis of the structural elements of ACTH/MSH peptides determining their ability to affect cognitive function. Neuroscience and Behavioral Physiology, 34(5), 457–463.

All content on this site is intended strictly for in vitro research and laboratory use. Products sold by Exceed Enhancement are not approved by the FDA and are not intended for human consumption, therapeutic use, or veterinary application.

Research-Grade Semax Available

Exceed Enhancement offers research-grade Semax for qualified research applications. View product specifications and ordering information →